Friday, July 10, 2026

pharma · Unresectable Hepatocellular Carcinoma (HCC) · Unexplained Recurrent Miscarriage and Recurrent Implantation Failure

Zenshine Pharmaceuticals

Nanjing Zenshine Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Unresectable Hepatocellular Carcinoma (HCC), Unexplained Recurrent Miscarriage and Recurrent Implanta

CN HQ
2018 Founded
12 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Founded
2018
Employees
12
Programs
8
Drugs
17
Patents
0
Clinical program

low-dose lymphocyte immunotherapy

Phase 2 · other · Unexplained Recurrent Miscarriage and Recurrent Implantation Failure

low-dose lymphocyte immunotherapy for Unexplained Recurrent Miscarriage and Recurrent Implantation Failure is a Phase 2 program (other) at Nanjing Zenshine Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Internal code BL2015007

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Nanjing Zenshine Pharmaceuticals
Phase
Phase 2
Modality
other
Indication
Unexplained Recurrent Miscarriage and Recurrent Implantation Failure
Status
completed
Trials
1